

Attorney Docket No.:
Inventors:
Serial No.:
Filing Date:
Page 3

KUZ0030US.NP.
Toshimitsu et al.
Not yet assigned
Herewith

10/577746

IAP17 Rec'd PCT/PTO 27 APR 2006

This listing of the claims will replace all prior versions
and listings of claims in the application:

Listing of the claims:

Claim 1 (original): A transdermal preparation
containing pergolide and/or a pharmaceutically acceptable
salt thereof, wherein said preparation is capable of
achieving a plasma AUC ratio of pergolide or the
pharmaceutically acceptable salt thereof to at least one
metabolite thereof of 1:0.5 to 1:5.

Claim 2 (original): The transdermal preparation
according to claim 1, wherein the plasma AUC ratio of
pergolide and/or a pharmaceutically acceptable salt thereof
to at least one metabolite thereof is 1:0.5 to 1:3.5.

Claim 3 (original): The transdermal preparation
according to claim 2, wherein the plasma AUC ratio of
pergolide and/or a pharmaceutically acceptable salt thereof
to at least one metabolite thereof is 1:0.5 to 1:2.

Attorney Docket No.: KUZ0030US.NP.
Inventors: Toshimitsu et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 4

Claim 4 (currently amended): The transdermal preparation according to ~~any one of claims 1 to 3~~ claim 1, wherein the metabolite is one or more kinds comprising pergolide sulfoxide, pergolide sulfone, despropyl pergolide or despropyl pergolide sulfoxide.

Claim 5 (original): The transdermal preparation according to claim 4, wherein the metabolite is pergolide sulfoxide.

Claim 6 (currently amended): The transdermal preparation according to ~~any one of claims 1 to 5~~ claim 1, wherein the pharmaceutically acceptable salt is one or more kinds comprising hydrochloride, sulfate, mesylate, citrate, fumarate, tartarate, maleate or acetate.

Claim 7 (original): The transdermal preparation according to claim 6, wherein the pharmaceutically acceptable salt is mesylate.

Claim 8 (currently amended): The transdermal preparation according to ~~any one of claims 1 to 7~~ claim 1, wherein the ratio (A/B) of the maximum plasma level (A) of

Attorney Docket No.: KUZ0030US.NP.
Inventors: Toshimitsu et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 5

pergolide and/or the pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration and/or the ratio (A'/B') of the maximum plasma level (A') of pergolide sulfoxide to the plasma level (B') of pergolide sulfoxide in the next administration is less than 2.

Claim 9 (currently amended): The transdermal preparation according to ~~any one of claims 1 to 8~~ claim 1, wherein (meth)acrylic acid copolymer is contained in an adhesive layer.

Claim 10 (original): The transdermal preparation according to claim 9, wherein the acrylic polymer except (meth)acrylic acid copolymer is further contained in an adhesive layer.

Claim 11 (original): A transdermal preparation containing pergolide and/or the pharmaceutically acceptable salt thereof, wherein the ratio (A/B) of the maximum plasma level (A) of pergolide and/or the pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration and/or the ratio (A'/B') of the

Attorney Docket No.: KUZ0030US.NP
Inventors: Toshimitsu et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 6

maximum plasma level (A') of pergolide sulfoxide to the
plasma level (B') of pergolide sulfoxide in the next
administration is less than 2.

Claim 12 (currently amended): The transdermal
preparation according to ~~any one of claims 1 to 11~~ claim 1,
wherein said preparation is an adhesive patch.